Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naghmeh Radhakrishna

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|December 26, 2022
Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic AsthmaVicky Kritikos, Erin S Harvey, Sean Stevens, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 8, 2019
Severe Asthma Global Evaluation (SAGE): An Electronic Platform for Severe AsthmaEve Denton, Fiona Hore-Lacy, Naghmeh Radhakrishna, et al.
Allergy|March 20, 2023
Trait profiles in difficult-to-treat asthma: Clinical impact and response to systematic assessmentTiffany Lin, Jonathan Pham, Eve Denton, et al.
Asia Pacific Allergy|November 14, 2019
Continued loss of asthma control following epidemic thunderstorm asthmaChuan T Foo, Ellen Ly Yee, Alan Young, et al.
BMC Pulmonary Medicine|October 11, 2015
An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosisJames B Geake, David W Reid, Bart J Currie, et al.
Plos One|March 21, 2015
Nontypeable Haemophilus influenzae induces sustained lung oxidative stress and protease expressionPaul T King, Roleen Sharma, Kim O'Sullivan, et al.
The European Respiratory Journal|March 7, 2020
Mepolizumab effectiveness and identification of super-responders in severe asthmaErin S Harvey, David Langton, Constance Katelaris, et al.
Respiratory Medicine|September 5, 2025
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab RegistryErin S Harvey, Yuto Hamada, Sarah A Hiles, et al.
Allergy|August 26, 2023
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patientsDennis Thomas, Vanessa M McDonald, Sean Stevens, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 5, 2021
Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab RegistryDennis Thomas, Erin S Harvey, Vanessa M McDonald, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
The Journal of Allergy and Clinical Immunology. in Practice|December 26, 2022
Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic AsthmaVicky Kritikos, Erin S Harvey, Sean Stevens, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 8, 2019
Severe Asthma Global Evaluation (SAGE): An Electronic Platform for Severe AsthmaEve Denton, Fiona Hore-Lacy, Naghmeh Radhakrishna, et al.
Allergy|March 20, 2023
Trait profiles in difficult-to-treat asthma: Clinical impact and response to systematic assessmentTiffany Lin, Jonathan Pham, Eve Denton, et al.
Asia Pacific Allergy|November 14, 2019
Continued loss of asthma control following epidemic thunderstorm asthmaChuan T Foo, Ellen Ly Yee, Alan Young, et al.
BMC Pulmonary Medicine|October 11, 2015
An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosisJames B Geake, David W Reid, Bart J Currie, et al.
Plos One|March 21, 2015
Nontypeable Haemophilus influenzae induces sustained lung oxidative stress and protease expressionPaul T King, Roleen Sharma, Kim O'Sullivan, et al.
The European Respiratory Journal|March 7, 2020
Mepolizumab effectiveness and identification of super-responders in severe asthmaErin S Harvey, David Langton, Constance Katelaris, et al.
Respiratory Medicine|September 5, 2025
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab RegistryErin S Harvey, Yuto Hamada, Sarah A Hiles, et al.
Allergy|August 26, 2023
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patientsDennis Thomas, Vanessa M McDonald, Sean Stevens, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 5, 2021
Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab RegistryDennis Thomas, Erin S Harvey, Vanessa M McDonald, et al.
Pageof 3